CN110075090A - A kind of salbutamol capsule and preparation method thereof for treating respiratory disorder - Google Patents
A kind of salbutamol capsule and preparation method thereof for treating respiratory disorder Download PDFInfo
- Publication number
- CN110075090A CN110075090A CN201910412883.XA CN201910412883A CN110075090A CN 110075090 A CN110075090 A CN 110075090A CN 201910412883 A CN201910412883 A CN 201910412883A CN 110075090 A CN110075090 A CN 110075090A
- Authority
- CN
- China
- Prior art keywords
- salbutamol
- parts
- composition
- particle
- label
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the preparation technical fields of compound, it is specially a kind of for treating the salbutamol capsule of respiratory disorder, including salbutamol composition A particle, salbutamol composition B particle, capsule shells, salbutamol composition A particle, salbutamol composition B particle are filled in the capsule shells, wherein salbutamol composition A particle, salbutamol composition B particle mass ratio be 1-1.5:1.A kind of preparation method of salbutamol capsule is also disclosed simultaneously.Capsule of the invention uses two kinds of salbutamol labels of A, B, and after disposably taking drugs, the concentration of monomer is constant, but since the dissolution time of two labels is inconsistent, dosing interval clinically is 8-12 hours, for the patient, reduce dosing interval, it is convenient to take.
Description
Technical field
The present invention relates to the preparation technical fields of compound, more particularly to a kind of for treating the husky butylamine of respiratory disorder
Alcohol capsule and preparation method thereof.
Background technique
Salbutamol is selectivity B2 receptor stimulating agent, has preferable bronchiectatic activity, is used clinically for treating
Bronchial asthma disease.Its dosage form of salbutamol has tablet, capsule, aerosol and injection etc., and salbutamol is selectivity β 2
Receptor stimulating agent can effectively inhibit the release that histamine etc. causes anaphylaxis substance, prevent bronchial spasm.It roars suitable for bronchus
The diseases such as asthma, asthmatic bronchitis, bronchial spasm, pulmonary emphysema.
And the most common dosage form of salbutamol in the prior art is capsule, especially presses top layer controlled release capsule.And show
Have main problem existing for the husky butanolamine control capsule in technology to be: 1, the half-life period of salbutamol is shorter, clinically needs
It is spaced medication in 6-8 hours, is inconvenient for the patient of long-term use, but the concentration of simple raising drug, it is right
The drug resistance for causing patient, influences drug effect, it is often more important that, it is easy to produce toxic side effect；2, salbutamol in the prior art
Preparation process it is cumbersome, at high cost.
Summary of the invention
The technical problem to be solved by the present invention is to, 1, the half-life period of salbutamol it is shorter, clinically need to be spaced 6-8 small
When medication, be inconvenient for the patient of long-term use, but the concentration of simple raising drug, to causing patient to resist
Pharmacological property influences drug effect, it is often more important that, it is easy to produce toxic side effect；2, the preparation process of salbutamol in the prior art is numerous
It is trivial, at high cost.
To solve the above problems, the invention discloses:
It is a kind of for treating the salbutamol capsule of respiratory disorder, including salbutamol composition A particle, salbutamol composition
B particle, capsule shells, the capsule shells are interior to fill salbutamol composition A particle, salbutamol composition B particle, wherein husky
Butylamine alcohol composition A particle, salbutamol composition B particle mass ratio be 1-1.5:1；Described salbutamol composition A
Grain includes the component of following parts by weight:
6-10 parts of salbutamol；
5-10 parts of ethyl cellulose；
Starch: 50-100 parts；
2-10 parts of magnesium stearate；
5-15 parts of sucrose fatty ester；
15-20 parts of lauryl sodium sulfate；
Appropriate coating agent；
Salbutamol composition B particle includes the component of following parts by weight:
8-12 parts of salbutamol；
5-10 parts of ethyl cellulose；
Starch: 40-80 parts；
2-10 parts of magnesium stearate；
5-15 parts of sucrose fatty ester；
15-20 parts of lauryl sodium sulfate；
Appropriate mucilage；
Appropriate coating agent.
Further technical solution of the invention, mucilage are the one of which of gelatin, Arabic gum, CAP.
Further technical solution of the invention, coating agent include syrup, talcum powder, edible pigment, cellulose derivative.
Further technical solution of the invention, the matter of salbutamol composition A particle, salbutamol composition B particle
Amount is than being 1.2:1；The salbutamol composition A particle includes the component of following parts by weight:
8 parts of salbutamol；
7 parts of ethyl cellulose；
Starch: 75 parts；
7 parts of magnesium stearate；
9 parts of sucrose fatty ester；
18 parts of lauryl sodium sulfate；
Appropriate coating agent；
Salbutamol composition B particle includes the component of following parts by weight:
10 parts of salbutamol；
7 parts of ethyl cellulose；
Starch: 60 parts；
7 parts of magnesium stearate；
9 parts of sucrose fatty ester；
18 parts of lauryl sodium sulfate；
Appropriate mucilage；
Appropriate coating agent.
The invention also discloses a kind of for treating the salbutamol capsule of respiratory disorder, comprises the following steps that:
S1, the preparation of salbutamol composition A particle, by salbutamol, ethyl cellulose, starch, magnesium stearate, Sucrose Fatty Acid Ester
Fat acid esters, lauryl sodium sulfate are uniformly mixed according to the weight ratio, ethyl alcohol are added as wetting agent, oscillating granulation crosses 100
Mesh obtains salbutamol composition A label；
S2, salbutamol composition A label coating, coating agent is dissolved using ethanol wet, coating agent liquid is made, by husky butylamine
Alcohol composition A label is placed in fluidized bed, is passed through air-flow, then by coating agent liquid atomizing spray to salbutamol composition A piece
Coating membrane is formed on core；40-55 degrees Celsius of drying；Obtain salbutamol composition A particle；
S3, the preparation of salbutamol composition B particle, by salbutamol, ethyl cellulose, starch, magnesium stearate, Sucrose Fatty Acid Ester
Fat acid esters, lauryl sodium sulfate are uniformly mixed according to the weight ratio, ethyl alcohol are added as wetting agent, oscillating granulation crosses 100
Mesh obtains salbutamol composition B label；
S4, salbutamol composition B label packet paddle will be sprayed mucilage in salbutamol composition B label using packet pulp grinder
On, rear 40-50 degrees Celsius of drying is sprayed, is sprayed again after drying；
S5, salbutamol composition B label coating, coating agent is dissolved using ethanol wet, coating agent liquid is made, after packet slurry
Salbutamol composition B label be placed in fluidized bed, air-flow is passed through, then by coating agent liquid atomizing spray to salbutamol group
It closes and forms coating membrane on object B label；40-55 degrees Celsius of drying obtains salbutamol composition B particle；
The mass ratio of salbutamol composition A particle, salbutamol composition B particle is uniformly mixed for 1-1.5:1, sets by S6
In in capsule shells.
Further technical solution of the invention, S2 spray coating, spray forms 12-15 layers of coating membrane altogether.
Further technical solution of the invention, S5 spray coating, spray forms 15-18 layers of coating membrane altogether.
Further technical solution of the invention wraps slurry in S4, sprays to form 3-5 layer packet and starch altogether.
Compared with prior art, the invention has the benefit that 1, capsule of the invention uses two seed sand butylamine of A, B
Alcohol label since the content of A label is lower than B label, and is additionally provided with packet slurry outside B label, therefore the digestion dissolution of B label in vivo
Speed is slow, and therefore, after disposably taking drugs, bioavailability in vivo is high, and the concentration of good drug efficacy, monomer is constant,
But since the dissolution time of two labels is inconsistent, dosing interval clinically is 8-12 hours, for the patient, is reduced
Dosing interval, it is convenient to take.
2, preparation method simple process of the invention, and it is at low cost, while by the improvement of technique, so that salbutamol group
Close object A particle, salbutamol composition B particle preparation process prepare respectively, the preparation speed of dosage form is fast, and effect is good.
Specific embodiment
With reference to embodiment, the present invention is furture elucidated, it should be understood that following specific embodiments are only used for
It is bright the present invention rather than limit the scope of the invention.
Embodiment 1
It is a kind of for treating the salbutamol capsule of respiratory disorder, including salbutamol composition A particle, salbutamol composition
B particle, capsule shells, the capsule shells are interior to fill salbutamol composition A particle, salbutamol composition B particle, wherein husky
Butylamine alcohol composition A particle, salbutamol composition B particle mass ratio be 1:1；The salbutamol composition A particle packet
Include the component of following parts by weight:
6 parts of salbutamol；
5 parts of ethyl cellulose；
Starch: 50- parts；
2 parts of magnesium stearate；
5 parts of sucrose fatty ester；
15 parts of lauryl sodium sulfate；
10 parts of coating agent；
Salbutamol composition B particle includes the component of following parts by weight:
8 parts of salbutamol；
5 parts of ethyl cellulose；
Starch: 40 parts；
2 parts of magnesium stearate；
5 parts of sucrose fatty ester；
15 parts of lauryl sodium sulfate；
10 parts of gelatin；
15 parts of coating agent.
Wherein, coating agent includes that syrup, talcum powder, edible pigment, cellulose derivative are mixed to get.
Embodiment 2
It is a kind of for treating the salbutamol capsule of respiratory disorder, including salbutamol composition A particle, salbutamol composition
B particle, capsule shells, the capsule shells are interior to fill salbutamol composition A particle, salbutamol composition B particle, wherein husky
Butylamine alcohol composition A particle, salbutamol composition B particle mass ratio be 1.5:1；The salbutamol composition A particle
Component including following parts by weight:
10 parts of salbutamol；
10 parts of ethyl cellulose；
Starch: 100 parts；
10 parts of magnesium stearate；
15 parts of sucrose fatty ester；
20 parts of lauryl sodium sulfate；
Coating agent 15；
Salbutamol composition B particle includes the component of following parts by weight:
8-12 parts of salbutamol；
5-10 parts of ethyl cellulose；
Starch: 40-80 parts；
2-10 parts of magnesium stearate；
5-15 parts of sucrose fatty ester；
15-20 parts of lauryl sodium sulfate；
15 parts of Arabic gum；
20 parts of coating agent.
Wherein, coating agent includes that syrup, talcum powder, edible pigment, cellulose derivative are mixed to get.
Embodiment 3
It is a kind of for treating the salbutamol capsule of respiratory disorder, salbutamol composition A particle, salbutamol composition B
The mass ratio of grain is 1.2:1；The salbutamol composition A particle includes the component of following parts by weight:
8 parts of salbutamol；
7 parts of ethyl cellulose；
Starch: 75 parts；
7 parts of magnesium stearate；
9 parts of sucrose fatty ester；
18 parts of lauryl sodium sulfate；
Appropriate coating agent；
Salbutamol composition B particle includes the component of following parts by weight:
10 parts of salbutamol；
7 parts of ethyl cellulose；
Starch: 60 parts；
7 parts of magnesium stearate；
9 parts of sucrose fatty ester；
18 parts of lauryl sodium sulfate；
12 parts of glue CAP；
18 parts of coating agent.
Wherein, coating agent includes that syrup, talcum powder, edible pigment, cellulose derivative are mixed to get.
Embodiment 4
The preparation method of the capsule of embodiment 1, comprises the following steps that:
S1, the preparation of salbutamol composition A particle, by salbutamol, ethyl cellulose, starch, magnesium stearate, Sucrose Fatty Acid Ester
Fat acid esters, lauryl sodium sulfate are uniformly mixed according to the weight ratio, ethyl alcohol are added as wetting agent, oscillating granulation crosses 100
Mesh obtains salbutamol composition A label；
S2, salbutamol composition A label coating, coating agent is dissolved using ethanol wet, coating agent liquid is made, by husky butylamine
Alcohol composition A label is placed in fluidized bed, is passed through air-flow, then by coating agent liquid atomizing spray to salbutamol composition A piece
Coating membrane is formed on core；40 degrees Celsius of dryings；Obtain salbutamol composition A particle；
S3, the preparation of salbutamol composition B particle, by salbutamol, ethyl cellulose, starch, magnesium stearate, Sucrose Fatty Acid Ester
Fat acid esters, lauryl sodium sulfate are uniformly mixed according to the weight ratio, ethyl alcohol are added as wetting agent, oscillating granulation crosses 100
Mesh obtains salbutamol composition B label；
S4, salbutamol composition B label packet paddle will be sprayed mucilage in salbutamol composition B label using packet pulp grinder
On, rear 40-50 degrees Celsius of drying is sprayed, is sprayed again after drying；
S5, salbutamol composition B label coating, coating agent is dissolved using ethanol wet, coating agent liquid is made, after packet slurry
Salbutamol composition B label be placed in fluidized bed, air-flow is passed through, then by coating agent liquid atomizing spray to salbutamol group
It closes and forms coating membrane on object B label；40 degrees Celsius of dryings obtain salbutamol composition B particle；
The mass ratio of salbutamol composition A particle, salbutamol composition B particle is uniformly mixed for 1:1, is placed in glue by S6
In softgel shell.
Wherein, S2 spray coating, spray forms 12 layers of coating membrane altogether；S5 spray coating, spray forms 15 layers of coating altogether
Film.
Wherein, slurry is wrapped in S4, sprays to form 3 layers of packet slurry altogether.
Embodiment 5
The preparation method of the capsule of embodiment 2, comprises the following steps that:
S1, the preparation of salbutamol composition A particle, by salbutamol, ethyl cellulose, starch, magnesium stearate, Sucrose Fatty Acid Ester
Fat acid esters, lauryl sodium sulfate are uniformly mixed according to the weight ratio, ethyl alcohol are added as wetting agent, oscillating granulation crosses 100
Mesh obtains salbutamol composition A label；
S2, salbutamol composition A label coating, coating agent is dissolved using ethanol wet, coating agent liquid is made, by husky butylamine
Alcohol composition A label is placed in fluidized bed, is passed through air-flow, then by coating agent liquid atomizing spray to salbutamol composition A piece
Coating membrane is formed on core；55 degrees Celsius of dryings；Obtain salbutamol composition A particle；
S3, the preparation of salbutamol composition B particle, by salbutamol, ethyl cellulose, starch, magnesium stearate, Sucrose Fatty Acid Ester
Fat acid esters, lauryl sodium sulfate are uniformly mixed according to the weight ratio, ethyl alcohol are added as wetting agent, oscillating granulation crosses 100
Mesh obtains salbutamol composition B label；
S4, salbutamol composition B label packet paddle will be sprayed mucilage in salbutamol composition B label using packet pulp grinder
On, 50 degrees Celsius of drying, spray again after drying after spraying；
S5, salbutamol composition B label coating, coating agent is dissolved using ethanol wet, coating agent liquid is made, after packet slurry
Salbutamol composition B label be placed in fluidized bed, air-flow is passed through, then by coating agent liquid atomizing spray to salbutamol group
It closes and forms coating membrane on object B label；55 degrees Celsius of dryings obtain salbutamol composition B particle；
The mass ratio of salbutamol composition A particle, salbutamol composition B particle is uniformly mixed for 1.5:1, is placed in by S6
In capsule shells.
Wherein, S2 spray coating, spray forms 15 layers of coating membrane altogether；S5 spray coating, spray forms 18 layers of coating altogether
Film.
Wherein, slurry is wrapped in S4, sprays to form 5 layers of packet slurry altogether.
Embodiment 6
The preparation method of the capsule of embodiment 3, comprises the following steps that:
S1, the preparation of salbutamol composition A particle, by salbutamol, ethyl cellulose, starch, magnesium stearate, Sucrose Fatty Acid Ester
Fat acid esters, lauryl sodium sulfate are uniformly mixed according to the weight ratio, ethyl alcohol are added as wetting agent, oscillating granulation crosses 100
Mesh obtains salbutamol composition A label；
S2, salbutamol composition A label coating, coating agent is dissolved using ethanol wet, coating agent liquid is made, by husky butylamine
Alcohol composition A label is placed in fluidized bed, is passed through air-flow, then by coating agent liquid atomizing spray to salbutamol composition A piece
Coating membrane is formed on core；50 degrees Celsius of dryings；Obtain salbutamol composition A particle；
S3, the preparation of salbutamol composition B particle, by salbutamol, ethyl cellulose, starch, magnesium stearate, Sucrose Fatty Acid Ester
Fat acid esters, lauryl sodium sulfate are uniformly mixed according to the weight ratio, ethyl alcohol are added as wetting agent, oscillating granulation crosses 100
Mesh obtains salbutamol composition B label；
S4, salbutamol composition B label packet paddle will be sprayed mucilage in salbutamol composition B label using packet pulp grinder
On, 48 degrees Celsius of drying, spray again after drying after spraying；
S5, salbutamol composition B label coating, coating agent is dissolved using ethanol wet, coating agent liquid is made, after packet slurry
Salbutamol composition B label be placed in fluidized bed, air-flow is passed through, then by coating agent liquid atomizing spray to salbutamol group
It closes and forms coating membrane on object B label；50 degrees Celsius of dryings obtain salbutamol composition B particle；
The mass ratio of salbutamol composition A particle, salbutamol composition B particle is uniformly mixed for 1.2:1, is placed in by S6
In capsule shells.
Wherein, S2 spray coating, spray forms 13 layers of coating membrane altogether；S5 spray coating, spray forms 17 layers of coating altogether
Film.
Wherein, slurry is wrapped in S4, sprays to form 4 layers of packet slurry altogether.
The technical means disclosed in the embodiments of the present invention is not limited only to technological means disclosed in above embodiment, further includes
Technical solution consisting of any combination of the above technical features.It should be pointed out that for those skilled in the art
For, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also considered as
Protection scope of the present invention.
Claims (8)
1. a kind of for treating the salbutamol capsule of respiratory disorder, it is characterised in that:
Including salbutamol composition A particle, salbutamol composition B particle, capsule shells, husky fourth is filled in the capsule shells
Amine alcohol composition A particle, salbutamol composition B particle, wherein salbutamol composition A particle, salbutamol composition B
The mass ratio of particle is 1-1.5:1；The salbutamol composition A particle includes the component of following parts by weight:
6-10 parts of salbutamol；
5-10 parts of ethyl cellulose；
Starch: 50-100 parts；
2-10 parts of magnesium stearate；
5-15 parts of sucrose fatty ester；
15-20 parts of lauryl sodium sulfate；
Appropriate coating agent；
Salbutamol composition B particle includes the component of following parts by weight:
8-12 parts of salbutamol；
5-10 parts of ethyl cellulose；
Starch: 40-80 parts；
2-10 parts of magnesium stearate；
5-15 parts of sucrose fatty ester；
15-20 parts of lauryl sodium sulfate；
Appropriate mucilage；
Appropriate coating agent.
2. salbutamol capsule as described in claim 1, it is characterised in that: mucilage be gelatin, Arabic gum, CAP its
Middle one kind.
3. salbutamol capsule as described in claim 1, it is characterised in that: coating agent includes syrup, talcum powder, edible color
Element, cellulose derivative.
4. salbutamol capsule as described in claim 1, it is characterised in that:
Salbutamol composition A particle, salbutamol composition B particle mass ratio be 1.2:1；The salbutamol combination
Object A particle includes the component of following parts by weight:
8 parts of salbutamol；
7 parts of ethyl cellulose；
Starch: 75 parts；
7 parts of magnesium stearate；
9 parts of sucrose fatty ester；
18 parts of lauryl sodium sulfate；
Appropriate coating agent；
Salbutamol composition B particle includes the component of following parts by weight:
10 parts of salbutamol；
7 parts of ethyl cellulose；
Starch: 60 parts；
7 parts of magnesium stearate；
9 parts of sucrose fatty ester；
18 parts of lauryl sodium sulfate；
Appropriate mucilage；
Appropriate coating agent.
5. a kind of for treating the preparation method of the salbutamol capsule of respiratory disorder, it is characterised in that:
It comprises the following steps that:
S1, the preparation of salbutamol composition A particle, by salbutamol, ethyl cellulose, starch, magnesium stearate, Sucrose Fatty Acid Ester
Fat acid esters, lauryl sodium sulfate are uniformly mixed according to the weight ratio, ethyl alcohol are added as wetting agent, oscillating granulation crosses 100
Mesh obtains salbutamol composition A label；
S2, salbutamol composition A label coating, coating agent is dissolved using ethanol wet, coating agent liquid is made, by husky butylamine
Alcohol composition A label is placed in fluidized bed, is passed through air-flow, then by coating agent liquid atomizing spray to salbutamol composition A piece
Coating membrane is formed on core；40-55 degrees Celsius of drying；Obtain salbutamol composition A particle；
S3, the preparation of salbutamol composition B particle, by salbutamol, ethyl cellulose, starch, magnesium stearate, Sucrose Fatty Acid Ester
Fat acid esters, lauryl sodium sulfate are uniformly mixed according to the weight ratio, ethyl alcohol are added as wetting agent, oscillating granulation crosses 100
Mesh obtains salbutamol composition B label；
S4, salbutamol composition B label packet paddle will be sprayed mucilage in salbutamol composition B label using packet pulp grinder
On, rear 40-50 degrees Celsius of drying is sprayed, is sprayed again after drying；
S5, salbutamol composition B label coating, coating agent is dissolved using ethanol wet, coating agent liquid is made, after packet slurry
Salbutamol composition B label be placed in fluidized bed, air-flow is passed through, then by coating agent liquid atomizing spray to salbutamol group
It closes and forms coating membrane on object B label；40-55 degrees Celsius of drying obtains salbutamol composition B particle；
The mass ratio of salbutamol composition A particle, salbutamol composition B particle is uniformly mixed for 1-1.5:1, sets by S6
In in capsule shells.
6. preparation method as claimed in claim 5, it is characterised in that: S2 spray coating, spray forms 12-15 layers of coating altogether
Film.
7. preparation method as claimed in claim 5, it is characterised in that: S5 spray coating, spray forms 15-18 layers of coating altogether
Film.
8. preparation method as claimed in claim 5, it is characterised in that: wrap slurry in S4, spray to form 3-5 layers of packet slurry altogether.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910412883.XA CN110075090A (en) | 2019-05-17 | 2019-05-17 | A kind of salbutamol capsule and preparation method thereof for treating respiratory disorder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910412883.XA CN110075090A (en) | 2019-05-17 | 2019-05-17 | A kind of salbutamol capsule and preparation method thereof for treating respiratory disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110075090A true CN110075090A (en) | 2019-08-02 |
Family
ID=67420664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910412883.XA Pending CN110075090A (en) | 2019-05-17 | 2019-05-17 | A kind of salbutamol capsule and preparation method thereof for treating respiratory disorder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110075090A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| CN102429892A (en) * | 2011-12-06 | 2012-05-02 | 江苏大学 | Levalbuterol sulfate pulsatile capsule and preparation method thereof |
| CN105963384A (en) * | 2016-06-12 | 2016-09-28 | 蚌埠丰原涂山制药有限公司 | Antiasthmatic drug composition and double-pulse controlled-release pellet capsules thereof and preparation method |
-
2019
- 2019-05-17 CN CN201910412883.XA patent/CN110075090A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| CN102429892A (en) * | 2011-12-06 | 2012-05-02 | 江苏大学 | Levalbuterol sulfate pulsatile capsule and preparation method thereof |
| CN105963384A (en) * | 2016-06-12 | 2016-09-28 | 蚌埠丰原涂山制药有限公司 | Antiasthmatic drug composition and double-pulse controlled-release pellet capsules thereof and preparation method |
Non-Patent Citations (2)
| Title |
|---|
| CHAUDHARI PM: "Formulation and evaluation of multiparticulate system for chronotherapeutic delivery of salbutamol sulphate", 《JOURNAL OF PHARMACY AND BIOALLIED SCIENCES》 * |
| 林朝霞: "硫酸沙丁胺醇哮喘时辰治疗药的制备及其体外释放度", 《中国医药导报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2038245C (en) | Pharmaceutically useful micropellets | |
| CN101647789B (en) | Levetiracetam slow release pellet capsule preparation | |
| CN102274205B (en) | Metoprolol succinate sustained-release capsule and preparation method | |
| CN101448493A (en) | Duloxetine hydrochloride delayed release formulations | |
| CN104352441B (en) | A kind of dimethyl fumarate enteric-coated micro-pill and preparation method thereof | |
| CN103315965A (en) | Oral solid granule suitable for infants and children, and preparation method thereof | |
| CN109771372A (en) | A kind of dextromethorphan hydrobromide sustained-release suspension and preparation method thereof | |
| CN107982241B (en) | Potassium sodium dehydroandroan drographolide succinate enteric preparation and preparation method thereof | |
| CN101596174B (en) | Soft capsule and preparation method thereof | |
| CN110075090A (en) | A kind of salbutamol capsule and preparation method thereof for treating respiratory disorder | |
| CN105434398B (en) | A kind of Rabeprazole enteric-coated micro-pill and preparation method thereof | |
| KR20160028460A (en) | Preparation method of traditional chinese medicine micro drop pill and traditional chinese medicine micro drop pill prepared by using the method | |
| CN103127220B (en) | Moisture-proof coating method used for traditional Chinese medicine salvia miltiorrhiza extract powder or particles | |
| UA122198C2 (en) | Salvia miltiorrhiza extract, micropellet formulation thereof, methods of preparing same, and uses thereof | |
| CN101120931A (en) | Bezafibrate sustained-release composition | |
| CN103191065A (en) | Celecoxib new formulation and preparation method thereof | |
| CN109925296A (en) | A kind of coating method of traditional Chinese medicine pellet | |
| MX2011005072A (en) | Novel method for preparing granulates of active principles, and granulates obtained thereof. | |
| CN101190186A (en) | 22R-budesonide colon-targeted pellets and preparation method thereof | |
| CN102068418B (en) | Sofalcone sustained-release pellet capsule preparation and preparation method thereof | |
| CN101879139A (en) | Enteric-coated preparation for treating digestive diseases and preparation method thereof | |
| CN102058563A (en) | Double-controlled release gliclazide sustained-release capsules and preparation method thereof | |
| CN104644761B (en) | Herba Cistanches ergosterol enteric-coated micro-pill | |
| CN106606499A (en) | Allopurinol sustained release capsules, and preparation method thereof | |
| CA2512434A1 (en) | Sustained-release pharmaceutical composition comprising carrageenan for lung administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190802 |
|
| RJ01 | Rejection of invention patent application after publication |